NYSE:PFE News 21 November 2025

Pfizer Stock (PFE) on December 8, 2025: Price, Dividend, New Drug Data and 2025–2030 Forecast

Pfizer Inc. (NYSE: PFE) heads into mid‑December 2025 as one of the market’s most hotly debated “high-yield value” healthcare stocks. The share price has stabilized around the mid‑$20s after a bruising multi‑year slide, even as the company delivers solid earnings,

8 December 2025

Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer Inc. (NYSE: PFE) is ending 2025 in better shape than it started, but investors are still debating whether the stock is a high‑yield value opportunity or a classic “value trap.” As of Friday, December 5, 2025, Pfizer shares closed

6 December 2025

Company News · Financial Forecasts · Investment Analysis · NYSE:PFE · Pharmaceutical Industry · Stock Market

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer, Inc. (NYSE: PFE) is back in focus on December 5, 2025, as investors weigh a near‑7% dividend yield, fresh analyst commentary, a major obesity‑drug acquisition and a slate of upcoming guidance that will shape expectations for 2026. Below is

5 December 2025

Financial Forecasts · Investment Strategies · NYSE:PFE · Obesity Treatment · Pfizer News · Stock Market

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Inc. (NYSE: PFE) remains one of the most closely watched healthcare stocks as of December 3, 2025. The share price is still stuck near post‑COVID lows, but a new $10 billion obesity‑drug acquisition, expanding RSV vaccine markets and a

3 December 2025

Financial Forecasts · Investment Strategies · NYSE:PFE · Pfizer Analysis · Pharmaceuticals · Stock Market

Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

As of late trading on Tuesday, December 2, 2025, Pfizer (NYSE: PFE) shares change hands around $25.10, down roughly 0.7% on the day and sitting in the middle of their 52‑week range of $20.92–$27.69. Yahoo Finance+1 The stock carries a dividend yield

2 December 2025

FDA Updates · Investment Outlook · NYSE:PFE · Pfizer News · Pharma Industry · Stock Analysis

Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

As U.S. markets prepare to reopen on Monday, December 1, 2025, Pfizer Inc. (NYSE: PFE) heads into the new week trading in a tight range but surrounded by a flurry of fresh analysis, institutional activity and strategic news from November

30 November 2025

Dividend Stocks · Financial Analysis · Investing · NYSE:PFE · Pharmaceuticals · Stock Market

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer Inc. (NYSE: PFE) is back in the spotlight as of November 30, 2025. Fresh regulatory filings show new institutional buying, analysts are nudging price targets higher, and the company has closed a multibillion‑dollar obesity deal while reshaping its post‑pandemic

30 November 2025

Dividend Investing · Institutional Investors · NYSE:PFE · Pfizer · Pharmaceutical Industry · Stock Market

Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield

Published: November 28, 2025 – mid‑session U.S. trading Pfizer stock price today: PFE edges higher in midday trade Pfizer stock (NYSE: PFE) is trading around $25.8 per share in late morning trading on Friday, November 28, 2025, up roughly 0.3%

28 November 2025

Dividend Stocks · Financial Analysis · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Inc. (NYSE: PFE) spent Wednesday trading slightly lower despite a stream of fresh headlines that cut both ways for sentiment. The stock hovered around $25.7, giving back a fraction of Tuesday’s nearly 2% gain, as investors weighed upbeat news

26 November 2025

Cancer Research · Legal Issues · NYSE:PFE · Obesity · Pharmaceuticals · Stocks

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer Inc. (NYSE: PFE) heads into Wednesday, November 26, 2025 with its share price sitting just under the top of its recent trading range and a narrative that looks very different from the COVID‑era boom and bust. After climbing almost

26 November 2025

Financial Analysis · Health Trends · Investment Strategies · NYSE:PFE · Pharmaceuticals · Stock Market

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer Inc. (NYSE: PFE) is back on many traders’ screens today. As of early afternoon on Tuesday, November 25, 2025, Pfizer shares are trading around $25.65, up roughly 1.7% on the session, after touching an intraday high near $25.96 and

25 November 2025

Health Business · Investment Analysis · NYSE:PFE · Pfizer News · Pharmaceutical Industry · Stock Market

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer’s share price is back in the spotlight on Friday, November 21, 2025, as investors digest strong Phase 3 flu-vaccine data, a $6 billion bond sale to fund its obesity-drug deal, and ongoing debate around the company’s roughly 7% dividend

21 November 2025

Dividends · Financial Analysis · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market

NYSE:PFE News 21 November 2025 - 8 December 2025